Prostate Cancer News on BioPortfolio

MDxHealth raises 36mm through capital increase

MDxHealth SA molecular diagnostics for cancer grossed 36mm $44mm through the private placement of 9.99mm new shares at 3.60 a 5 discount. Proceeds will support continued development of SelectMDx prostate cancer biopsy test; commercialization activities for...

Liquid biopsy technology to improve prostate cancer treatment

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide according to 2012 numbers. While several viable treatment options for prostate cancer exist many men affected with prostate cancer wil...

Methionine Aminopeptidase 2 Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18 Pipeline Review H1 2018 Report Updated 27032018 Prices from USD $3500

Methionine Aminopeptidase 2 Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18 Pipeline Review H1 2018SummaryAccording to the recently published report 'Methionine Aminopeptidase 2...

Pages